Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
about
New treatment option for ovarian cancer: PARP inhibitorsRole of Biomarkers in the Development of PARP InhibitorsUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicRecent advances in targeted therapy for Ewing sarcomaSarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionSynergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiencyPharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.Precision medicine in pediatric oncology: Lessons learned and next steps.Novel insights and therapeutic interventions for pediatric osteosarcoma.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.WD40 repeat domain proteins: a novel target class?Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.
P2860
Q26745614-51047596-B7C4-46D5-B718-0A28DD858E72Q26753159-C64C3AD4-D856-4776-BE2A-62A99F553ED8Q28071541-9FD29745-CF50-4A48-A80E-9C25A9EFA4FBQ28079316-2D8B1913-8B20-4CDF-A371-12B025CD99C2Q35767389-FA18312A-0C56-42E1-BC4C-D1A9A1AC34CDQ36104739-BF61F08D-BC98-47D0-B21D-9F49D942C49EQ36392466-48168C80-F99B-45B1-9DD6-B2482BC3D371Q36489494-11B97648-184A-4F2E-885F-D9AD8C17F9E7Q38371672-041E6847-CE47-4C90-8E23-1396087C6CD0Q38753542-3073BE61-1E6A-4556-B7B5-5F81E646E64CQ38810911-E42889CE-1B14-46AD-B0F6-AB605922E0AAQ38819276-8035CADC-542A-4D44-B624-E2A7599CACADQ38837564-448BFD10-5773-4468-AC26-961BC4761566Q41472115-7E904B74-44A6-4C65-B31C-6A59CCE35B54Q47291150-08318527-C752-498B-9FB1-FA2839C6E174Q47786231-B7D56E04-65FB-47F5-9F3D-2FCB3B5F3758Q48103408-C917121F-6E04-442F-853D-308DC5186548Q48290610-0762496B-8618-453D-BCD7-972A3E60C30A
P2860
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Initial testing (stage 1) of t ...... l in vivo response to BMN 673.
@ast
Initial testing (stage 1) of t ...... l in vivo response to BMN 673.
@en
type
label
Initial testing (stage 1) of t ...... l in vivo response to BMN 673.
@ast
Initial testing (stage 1) of t ...... l in vivo response to BMN 673.
@en
prefLabel
Initial testing (stage 1) of t ...... l in vivo response to BMN 673.
@ast
Initial testing (stage 1) of t ...... l in vivo response to BMN 673.
@en
P2093
P2860
P50
P356
P1476
Initial testing (stage 1) of t ...... al in vivo response to BMN 673
@en
P2093
David A Wheeler
E Anders Kolb
Hernan Carol
Jianrong Wu
John M Maris
Oliver A Hampton
Peter J Houghton
Raushan T Kurmasheva
Stephen T Keir
P2860
P356
10.1002/PBC.25201
P577
2014-09-27T00:00:00Z